MDRNA is a biotechnology company focused on the development and commercialization
of therapeutic products based on RNA interference (RNAi). We are building a
broad, flexible and cutting-edge...
Article - 16 Sep 2009
RNA interference (RNAi) is a powerful strategy for suppressing gene expression in a sequence-specific manner.
News - 9 Sep 2009
Putting the next generation of medicines on pharmacy shelves hinges on an intensive search for ways of safely and effectively delivering a silencing message to genes that are at the basis of...
News - 5 Nov 2008
Thermo Fisher Scientific Inc., the world leader in serving science, has entered into a collaboration with Genentech, Inc. to develop novel small-interfering RNA (siRNA) therapeutic technologies for...
News - 22 Oct 2008
Dicerna Pharmaceuticals, Inc., an RNA interference company developing novel therapeutics in multiple disease areas, today announced that Bob D. Brown, Ph.D., senior vice president of research,...
News - 11 Nov 2009
Science and technology journalists pride themselves on the ability to explain complicated ideas in accessible ways, but there are some technical principles that we encounter so often in our reporting...
News - 25 Mar 2010
A team of researchers and clinicians from UCLA's Jonsson Comprehensive Cancer Center and the California Institute of Technology has published the first proof that a targeted nanoparticle - used as...
News - 7 Apr 2010
Officials of Kylin Therapeutics Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office (USPTO).
News - 25 Sep 2008
The EU-funded research project RIGHT ('RNA interference technology as human therapeutic tool') and the European Science Foundation (ESF) will hold a symposium on ribonucleic acid interference...
News - 25 Jun 2013
Nanoparticles that deliver short strands of RNA offer a way to treat cancer and other diseases by shutting off malfunctioning genes. Although this approach has shown some promise, scientists are still...